Table 1.

Baseline characteristics of nucleoside-refractory patients with chronic hepatitis B virus (HBV) infection (n=25)

^*The patient who had been referred due to a high viral load during lamivudine (LAM) plus adefovir dipivoxil (ADV) combination treatment and had previously had a LAM-resistant mutation.

HBeAg, hepatitis B e-antigen; AST, aspartate aminotransferase; ALT, alanine aminotrasferase; HBV, hepatitis B virus; ETV, entecavir; ADV, adefovir dipivoxil; LMV, lamivudine; NAs, nucleos(t)ide analogues.